Lymphomyosot minimizes the risks associated with diabetic neuropathy

Activates the lymphatic system

The efficacy of Lymphomyosot for the treatment and prevention of lymphatic disorders has been demonstrated in numerous studies¹–⁵.

Extremely well tolerated

In a study of 3,512 patients, including 1,124 (32%) children under 10 years of age, 99.8% assessed Lymphomyosot therapy as “very well tolerated” throughout the course of treatment¹.

3 different dosage forms

• Drops: 15 drops 3 times per day
• Tablets: 3 tablets 3 times per day
• Ampoules: 1 ampoule 1 to 3 times per week

As a standard for comparison, 10 infusions with 600 mg of α-lipoic acid over 8 months improved tactile sensitivity among study patients by only Ø +0.9. However, a combination therapy with Lymphomyosot (15 drops twice daily for 8 months) and α-lipoic acid (10 infusions with 600 mg of α-lipoic acid over 8 months) improved tactile sensitivity by Ø +3.25⁵.

• Neural nutrient insufficiency
• Diminished tactile sensitivity
• Defence reaction absent
• Risk, imbalance, damage
• Amputation
• Gangrene
• Diabetes
• Diabetic foot
• Inflammation
• Malfunction/glycosylation of the matrix
• Peri-neural oedema

Reduction of oedema

Severity of symptoms	Start	Reduction	No reduction
Slight	14	10	4
Moderate	26	19	7
Severe	0	9	1

50 patients diagnosed with diabetic neuropathy were administered 15 drops of Lymphomyosot twice daily for 8 months. At the end of the treatment period, lymphoedema and tactile sensitivity had profoundly improved⁵.

Improvement of tactile sensitivity

Severity of symptoms	Start	End	Difference
Slight	5.0	7.5	+2.5
Moderate	3.0	6.0	+3.0
Severe	0.0	3.0	+3.0

Minimizes the risks associated with diabetic neuropathy

• Improved matrix metabolism
• Improved tactile sensitivity
• Eliminated pain in 75% of patients
• Lymphatic disorders
• Recurrent infections
• Detoxification and drainage

Lymphomyosot – recommended for

• Lymphhoedema (i.e. for promoting postmammectomy drainage)
• A compromised defence system (i.e. for treating recurrent and acute infections, and inflammatory disorders such as tonsillitis or lymphangitis)
• Tonsillar hypertrophy
• Lymphadenitis
• Systemic toxicities (i.e. for treating chronic diseases or amalgam-related disorders)

Composition:

• Drops: 100 g cont.: Myosotis arvensis D3, Veronica officinalis D3, Teucrium scorodonia D3, Pinus silvestris D 4, Gentiana lutea D 5, Equisetum hyemale D4, Sarsaparilla D6, Scrophularia nodosa D3, Juglans regia D3, Calcium phosphoricum D12, Natrium sulfuricum D4, Fumaria officinalis D4, Levothyroxinum D12, Araneus diadematus D6 5 g each; Geranium robertianum D4, Nasturtium officinale D4, Ferrum jodatum D12 10 g each. Contains 35 vol.-% alcohol.
• Tablets: 1 tablet cont.: Myosotisarvensis D3, Veronica officinalis D3, Teucrium scorodonia D3, Pinus silvestris D4, Gentiana lutea D5, Equisetum hyemale ex herba rec. D4, Sarsaparilla D6, Scrophularia nodosa D3, Juglans regia D3, Calcium phosphoricum D12, Natrium sulfuricum D4, Fumaria officinalis D4, Levothyroxinum D12, Araneus diadematus D6 5 g each; Geranium robertianum D4, Nasturtium officinale D4, Ferrum jodatum D12 10 g each.
• Injection solution: 1.1 ml cont.: Myosotis arvensis D3, Veronica officinalis D3, Teucrium scorodonia D3, Pinus silvestris D4, Gentiana lutea D5, Equisetum hyemale D4, Sarsaparilla D6, Scrophularia nodosa D3, Juglans regia D3, Calcium phosphoricum D12, Natrium sulfuricum D4, Fumaria officinalis D4, Levothyroxinum D12, Araneus diadematus D6 0.55 µl each; Geranium robertianum D4, Nasturtium officinale D4, Ferrum jodatum D12 1.1 µl each.

Indications: Status lymphaticus (tendency to hyperdevelopment of the lymphatic organs; tendency to development of oedemas and infections); glandular swelling; tonsillar hypertrophy; chronic tonsillitis.
Contraindications: In case of thyroid disorders, this preparation may not be administered without prior approval from a physician.
Side effects: None known.
Interactions with other medication: None known.
Dosage: Drops: In general, 15-20 drops 3 times daily. Tablets: In general, 3 tablets to be dissolved in the mouth 3 times daily. Injection solution: In acute disorders daily, otherwise 3-1 times weekly 1 ampoule i.m., s.c., i.d.
Package sizes: Drops: Drop bottles containing 30 and 100 ml. Tablets: Packs containing 50 and 250 tablets. Injection solution: Packs containing 10, 50 and 100 ampoules of 1.1 ml.
Revised: April 2001.

References

1. Zenner S, Metelmann H: Therapeutic Use of Lymphomyosot® – Results of a Multicentre Use Observation Study on 3,512 Patients. Biological Therapy 1990, Vol Vlll No. 3.: 49–53,67–72, and Vol Vlll, No. 4: 79–84, 94
2. Küstermann K, Weiser M: Treatment of a Lymphatic Disease with Homoeopathic Therapy. Biologische Medizin 1997; Vol 26 No. 3: 110–114
3. Rinneberg A-L: Lymphomyosot®: The Therapy of Tonsillitis and Prophylaxis against its Recurrence. Biological Therapy 1991; Vol IX No. 1: 111–114
4. Riley D, White S: A Biotherapeutic Approach to the Treatment of Inflammatory Disorders: A Drug Monitoring Trial. Biological Therapy 1992; Vol. X No. 3: 267–271
5. Dietz R: Possibilities of Lymph Therapy with Diabetic Polyneuropathy. Biologische Medizin 2000; Vol 29 No. 1: 4–9